3. Review of FY 1996 expenditures, approval of FY 1997 proposed budget, and review of FY 1996 estimates.

CONTACT PERSON FOR MORE INFORMATION: Thomas J. Trabucco, Director, Office of Eternal Affairs, (202) 942–1640.

Date: September 3, 1996.

Roger W. Mehle,

Executive Director, Federal Retirement Thrift Investment Board.

[FR Doc. 96–22899 Filed 9–4–96; 9:48 am]

BILLING CODE 6760–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

Addressing Immunization Information Systems Barriers Meeting

The National Immunization Program (NIP) of the Centers for Disease Control and Prevention (CDC), announces the following meeting.

Name: Addressing Immunization Information Systems Barriers.

Time and Date: 9 a.m.-4 p.m., September 12, 1996.

Place: Office of the National Immunization Program, CDC, Corporate Square Office Park, Building 12, Third Floor Conference Room, Atlanta, Georgia 30329, telephone 404/639–8250.

Status: Open to the public for observation and comment, limited only by the space available. To reserve a seat, please pre-register by calling the contact person listed below.

Purpose: The purpose of this meeting is to identify barriers to the development and implementation of automated immunization information systems, and strategies to address these barriers. Agenda items will include discussion between information systems experts, public health officials, and other healthcare providers.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Jim Harrison, Director, Data Management Division, NIP, CDC, Corporate Square Boulevard, M/S E–62, Atlanta, Georgia 30329, telephone 404/639–8250.

Dated: August 28, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–22763 Filed 9–5–96; 8:45 am]

BILLING CODE 4163–18–M

Health Care Financing Administration

[Document Identifier: HCFA–1964]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summaries of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. HCFA–1964 *Type of Information Collection Request:* Reinstatement, without change, of previously approved collection for which approval has expired; *Title of Information Collection:* Request for Review of Part B Medicare Claim and Supporting regulation 42 CFR 405.807; *Form No.:* HCFA–1964; *Use:* This form is completed by beneficiaries, representative, or assignees who wish to pursue their statutory appeal rights by requesting a review of an initial determination made by a Part B carrier on a claim for medical and other health services. 42 CFR 405.807 is the regulation supporting this collection of information; *Frequency:* On occasion; *Affected Public:* Individuals or households, not for profit institutions; *Number of Respondents:* 7,200,000; *Total Annual Responses:* 7,200,000; *Total Annual Hours:* 1,800,000.

To obtain copies of the supporting statement for the proposed paperwork collections referenced above, access HCFA's WEB SITE ADDRESS at http://www.hcfa.gov, or to obtain the supporting statement and any related forms, E-mail your request, including your address and phone number, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Planning and Analysis Staff, Attention: John Burke, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: August 28, 1996.

Edwin J. Glatzel,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–22718 Filed 9–5–96; 8:45 am]

BILLING CODE 4120–03–P

[(HCFA-R–13, 2567–A]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposal for the collection of information. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection Request:* Revision of a currently approved collection; *Title of Information Collection:* Conditions of Coverage for Organ Procurement Organizations; *Form No.:* HCFA–R–13; *Use:* Organ procurement organizations are required to submit accurate data to HCFA concerning population and information on donors and organs on an annual basis in order to assure maximum effectiveness in the procurement and distribution of organs. Frequency: Annually; *Affected Public:* Not-for-profit institutions; *Number of Respondents:* 66; *Total Annual Responses:* 66; *Total Annual Hours Requested:* 1.

2. *Type of Information Collection Request:* Extension of a currently

approved collection; *Title of Information Collection:* Statement of Deficiencies and Plan of Correction; *Form No.:* HCFA–2567–A; *Use:* This Paperwork package provides information regarding deficiencies for Organ Procurement Organizations (OPO) as well as deficiencies noted during periodic facility and laboratory certification surveys. This information is used to make decisions concerning OPO redesignation, certification/recertification of health care facilities participating in the Medicare/Medicaid Programs, and laboratories regulated by CLIA. *Frequency:* Annually and Biennially; *Affected Public:* State, Local or Tribal Governments, Business or other for-profit, Not-for-profit institutions, and Federal Government; *Number of Respondents:* 49,200; *Total Annual Responses:* 98,400; *Total Annual Hours Requested:* 196,800.

To request copies of the proposed paperwork collections referenced above, E-mail your request, including your address, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 30 days of this notice directly to the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Date: August 28, 1996.

Edwin J. Glatzel,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–22714 Filed 9–5–96; 8:45 am]

BILLING CODE 4120–03–P

National Institutes of Health

Opportunity for a Cooperative Research and Development Agreement

National Heart, Lung and Blood Institute (NHLBI); Opportunity for a Cooperative Research and Development Agreement (CRADA) for the development of different therapeutic modalities to raise plasma concentrations of the enzyme lecithin cholesterol acyltransferase (LCAT) for the treatment of atherosclerosis and LCAT deficiency.

AGENCY: National Institutes of Health, PHS, HHS.

ACTION: Notice.

SUMMARY: In humans, the development of atherosclerosis is positively and inversely correlated with the plasma levels of low density lipoproteins (LDL) and high density lipoproteins (HDL) respectively. LCAT, the major enzyme involved in the esterification of free cholesterol present in circulating plasma lipoproteins, is a major determinant of plasma HDL concentrations. Recent studies have established that transgenic rabbits overexpressing human LCAT have 6–7 fold higher plasma HDL levels than control, non-transgenic siblings. In addition, LCAT transgenic rabbits have reduced plasma concentrations of the atherogenic LDL and apoB-containing lipoproteins. This lipoprotein phenotype characterized by elevated plasma HDL and reduced LDL levels leads to marked protection against the development of diet-induced atherosclerosis in LCAT transgenic rabbits compared to control animals.

The NHLBI of the NIH is seeking capability statements from parties interested in entering into a CRADA on the development of different therapeutic modalities to raise plasma concentrations of the enzyme lecithin cholesterol acyltransferase (LCAT) for the treatment of atherosclerosis and LCAT deficiency. This project is with the Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. The goals are to use the respective strengths of both parties to achieve one or more of the following:

(1) Evaluate the feasibility of gene therapy utilizing the LCAT gene and suitable vectors as a treatment approach for the prevention of atherosclerosis in animal models as well as patients with premature cardiovascular disease; and,

(2) Evaluate the use of gene therapy to correct LCAT deficiency in LCAT knockout mice models systems and patients with LCAT deficiency; and,

(3) Develop and evaluate the anti-atherogenic properties of pharmacological agents that raise plasma concentrations of LCAT.

It is anticipated that the commercial collaborator(s) will participate in ongoing studies on one or both of the research projects involving (1) the transfer of the human LCAT gene in animal models and patients with atherosclerosis or LCAT deficiency and (2) the development of pharmacologic agents that will increase plasma concentrations of LCAT. It is highly desirable that the collaborator have the resources to provide new effective vectors for the long term *in vivo* expression of the LCAT gene. The collaborator may also be expected to contribute financial support under this CRADA for supplies and personnel to support these projects.

CRADA capability statements should be submitted to Ms. Lili Portilla, Technology Transfer Specialist, National Heart, Lung, and Blood Institute, Technology Transfer and Commercialization Team, 31 Center Drive MSC 2490, Bldg. 31/Room 1B32, Bethesda, Maryland 20892–2490, Phone: (301) 402–5579, Fax: (301) 594–3080. Capability statements must be received by the NHLBI on or before October 7, 1996.

The NHLBI has applied for patents claiming this core technology. Non-exclusive and/or exclusive licenses for these patents covering core aspects of this project are available to interested parties. Licensing inquiries regarding this technology should be referred to Ms. Carol Lavrich, Licensing Specialist, NIH Office of Technology Transfer, 6011 Executive Blvd., Suite 325, Rockville, Maryland, 20852–3804, Phone: (301) 496–7735, Ext. 287, Fax: (301) 402–0220.

Dated: August 29, 1996.

Sheila Merritt,

Executive Officer, NHLBI.

[FR Doc. 96–22758 Filed 9–5–96; 8:45 am]

BILLING CODE 4140–01–M

National Library of Medicine; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Board of Regents, National Library of Medicine, September 24–25, 1996, Board Room of the National Library of Medicine, Building 38, which was published in the Federal Register on August 19, 1996. (61 FR 43066).

The meeting was to have been open to the public on September 24 from 9 a.m. to 4:30 p.m., but has been changed to be open from 9 a.m. to approximately 11:25 a.m. and 12 noon to approximately 4:15 p.m. The meeting was to have been closed to the public on September 24 from 4:30 to 5 p.m., but has been changed to be closed from 11:25 a.m. to 12 noon, and from 3:45 to 4:15 p.m.

As previously announced, the meeting will be open to the public on September 25 from 9 a.m. to adjournment.

Dated: August 30, 1996.

Margery G. Grubb,

Senior NIH Committee Management Specialist.

[FR Doc. 96–22757 Filed 9–5–96; 8:45 am]

BILLING CODE 4410–01–M